Luxxfolio Holdings Inc. has made a strategic investment in LitVM, a Layer 2 blockchain project aimed at bringing smart contract functionality and decentralized applications to the Litecoin network. This move supports Luxxfolio's broader strategy to enhance Litecoin's utility beyond payments, enabling new applications in decentralized finance and tokenized real-world assets. The investment aligns with Luxxfolio's existing mining and infrastructure activities and aims to drive long-term adoption and developer engagement within the Litecoin ecosystem. Luxxfolio plans to continue exploring opportunities that complement its focus on Litecoin and digital asset infrastructure.
Luxxfolio's strategic investment in LitVM is the focus, with Pluang market data providing context. As of Oct 13, 2026 22:41 WIB, out of 150 US stocks priced on Pluang, 59 rose and 90 fell. Notable movers include Plug Power Inc at USD 1.55 with a 4.01% decline, Pinterest Inc at USD 22.12 up 3.27%, and Li Auto Inc at USD 11.75 up 3.07%.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
